Table 1.
Baseline characteristics.
| Variables | ESRD (n = 10,498) | KT (n = 10,498) | Healthy controls (n = 10,498) | P-value |
|---|---|---|---|---|
| Age, years, n (%) | 45.87 ± 10.57 | 45.87 ± 10.57 | 45.87 ± 10.57 | > 0.999 |
| 20–29 | 771 (7.3) | 771 (7.3) | 771 (7.3) | |
| 30–39 | 2186 (20.8) | 2186 (20.8) | 2186 (20.8) | |
| 40–49 | 3378 (32.2) | 3378 (32.2) | 3378 (32.2) | |
| 50–59 | 3139 (29.9) | 3139 (29.9) | 3139 (29.9) | |
| 60–69 | 974 (9.3) | 974 (9.3) | 974 (9.3) | |
| 70–79 | 48 (0.5) | 48 (0.5) | 48 (0.5) | |
| ≥ 80 | 2 (0.02) | 2 (0.02) | 2 (0.02) | |
| Gender, male, n (%) | 6200 (59.1) | 6200 (59.1) | 6200 (59.1) | > 0.999 |
| Index year, n (%) | > 0.999 | |||
| 2007–2009 | 2628 (25.03) | 2628 (25.03) | 2628 (25.03) | |
| 2010–2012 | 3643 (34.7) | 3643 (34.7) | 3643 (34.7) | |
| 2013–2015 | 4227 (40.26) | 4227 (40.26) | 4227 (40.26) | |
| Income status, n (%) | ||||
| Medical aid | 2432 (23.17) | 1496 (14.25) | 261 (2.49) | |
| Q1 | 2895 (27.58) | 2111 (20.11) | 2710 (25.81) | |
| Q2 | 2179 (20.76) | 2056 (19.58) | 2570 (24.48) | |
| Q3 | 1751 (16.68) | 2204 (20.99) | 2449 (23.33) | |
| Q4 | 1241 (11.82) | 2631 (25.06) | 2508 (23.89) | |
| DM, n (%) | 4231 (40.3) | 4231 (40.3) | 661 (6.3) | < 0.001 |
| HTN, n (%) | 9576 (91.22) | 9576 (91.22) | 1748 (16.65) | < 0.001 |
| Dyslipidemia, n (%) | 4441 (42.3) | 5904 (56.24) | 1245 (11.86) | < 0.001 |
| Dialysis modality, n (%) | ||||
| Preemptive | 0 (0) | 3383 (32.23) | 10,498 (100) | |
| Hemodialysis | 7781 (74.12) | 4663 (44.42) | 0 (0) | |
| Peritoneal dialysis | 2145 (20.43) | 1777 (16.93) | 0 (0) | |
| Mixed | 572 (5.45) | 675 (6.43) | 0 (0) | |
| Desensitization, n (%) | < 0.001 | |||
| Yes | 0 (0) | 1619 (15.42) | 0 (0) | |
| No | 10,498 (100) | 8879 (84.58) | 10,498 (100) | |
| Induction, n (%) | < 0.001 | |||
| Not use | 10,498 (100) | 563 (5.36) | 10,498 (100) | |
| ATG | 0 (0) | 884 (8.42) | 0 (0) | |
| Basiliximab | 0 (0) | 9051 (86.22) | 0 (0) | |
| Maintenance, n (%) | < 0.001 | |||
| Not use | 10,498 (100) | 253 (2.41) | 10,498 (100) | |
| Tacrolimus | 0 (0) | 8565 (81.59) | 0 (0) | |
| Cyslosporine | 0 (0) | 1680 (16) | 0 (0) | |
Expressed with the number of cases (proportion). Comparison was performed using student t-test and chi-square test.
ATG anti-thymocyte globulin, CI confidence interval, ESRD end stage renal disease, DM diabetes mellitus, HTN hypertension, Income status divided into four income classes by National health insurance premium (Q1: lowest, Q4: highest), KT kidney transplantation.